AI
TERN

Atom Investors’s Terns Pharmaceuticals TERN Stock Holding History

Atom Investors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,825
Closed -$333K – 664
2024
Q1 		$333K Sell
50,825
-23,261
-31% -$152K 0.04% 396
2023
Q4 		$481K Sell
74,086
-26,632
-26% -$141K 0.08% 285
2023
Q3 		$507K Buy
100,718
+39,070
+63% +$248K 0.12% 229
2023
Q2 		$539K Buy
61,648
+9,697
+19% +$113K 0.2% 102
2023
Q1 		$615K Buy
+51,951
New +$496K 0.33% 81

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Atom Investors's TERN Position: Q2 2024 in Review

Atom Investors sold out of Terns Pharmaceuticals (TERN) in Q2 2024, closing a stake of 50,825 shares — an estimated $333K sold.

Atom Investors first reported a position in TERN in Q1 2023 and held it in 5 quarters. The position peaked at $615K in Q1 2023. 126 funds tracked by Wall St. Rank hold TERN as of Q2 2024.

  • Atom Investors reported no remaining Terns Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 50,825 Terns Pharmaceuticals shares in Q2 2024, an estimated $333K.
  • Atom Investors first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Atom Investors's Terns Pharmaceuticals position peaked at $615K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.